From The Reimbursed Personal Genome—-Five Years Away?:

Mark Rubin

Mark Rubin—

Director of New York’s Institute for Precision Medicine

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

Sponsored · Whitepaper
How Big Is the US Market for Medical Devices & Technologies?
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Xconomy on Demand

We offer a number of ways to subscribe for free!